12. Kumar S, Bhatia M, Behari M . Sleep disorders in Parkinson \200\231s disease. Mov Disord 2002; 17 : 775 \200\2238 1 . 35. Overeem S, van Hilten JJ, Ripley B, Mignot E, Nishino S, Lammers GJ . Normal hypocretin - 1 levels in Parkinson \200\231s disease patients with excessive daytime sleepiness. Neuro logy 2002; 58 : 498 \200\2239 . 13. Maria B, Sophia S, Michalis M, et al . Sleep breathing disorders in patients with idiopathic Parkinson \200\231s disease. Respir Med 2003; 97 : 1151 \200\2237 . 36. Baumann C, Ferini-Strambi L, Waldvogel D, Werth E, Bassetti CL . Parkinsonism with exce ssive daytime sleepiness \200\224a narcolepsy-lik e dis- order? J Neurol 2005 ; 252 : 139 \200\2234 5 . 14. Trenkwalder C, Kies B, Rudzinska M, et al . Rotigotine eff ects on early morning motor function and sleep in Parkinson \200\231s disease: a double-blin d, randomized, placebo-con trolle d study (RECOVER). Mov Disord 2011; 26 : 90 \200\2239 . 37. Compta Y, Santamaria J, Ratti L, et al. Cerebrospinal hypocretin, daytime sleepiness an d sleep architecture in Parkinson \200\231s disease dementia. Brain 2009 ; 132 : 3308 \200 \2231 7 . 15. Pahwa R, Stacy MA, Factor SA, et al . Ropinirole 24-hou r prolonged release: randomized , controlled study in advanced Parkinson disease. Neurology 2007; 68 : 1108 \200\2231 5 . 38. Rye DB . Th e two faces of Eve: dopamine \200\231s modulation of wakefulness and sleep. Neurology 2004; 63 (Suppl 3): S2 \200\2237 . 16. Menza M, Dobkin RD, Marin H, et al . Treatment of insomnia in Parkinson \200\231s disea se: a controlled trial of eszopiclone and placebo. Mov Disord 2010; 25 (11): 1708 \200\2231 4 . 39. Fronczek R, Overeem S, Lee SY, et al . Hypocretin (orexin) loss in Parkinson \200\231s disease. Brain 2007; 130 : 1577 \200\2238 5 . 17. Iranzo A, Santamaria J, Tolosa E . Th e clinical and pathophysiological rel- evance of REM sleep behavior disorder in neurodegenerative diseases. Sleep Med Rev 2009; 13 : 385 \200\22340 1 . 40. Th annickal TC, Lai YY, Siegel JM . Hypocretin (orexin) cell loss in Parkinson \200\231s disease. Brain 2007; 130 : 1586 \200\2239 5 . 41. Fabbrini G, Barbanti P, Aurilia C, Vanacore N, Pauletti C, Meco G . Excessive daytime s leepiness in de novo and treated Parkinson \200\231s disease. Mov Disord 2002; 17 : 1026 \200\2233 0 . 18. Schenck CH, Mahowald MW . REM sleep behavior disorder: clinical, developmental, and neu roscience perspectives 16 years aft er its formal identifi cation in SLEEP. Sleep 2002; 25 : 120 \200\2233 8 . 42. Gjerstad MD, Aarsland D, Larsen JP . Development of daytime somno- lence over time in P arkinson \200\231s disease. Neurology 2002; 58 : 1544 \200\2236 . 43. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S . Falling asleep at the wheel: motor vehicle mishaps in perso ns taking pramipexole and rop- inirole. Neurology 1999; 52 : 1908 \200\2231 0 . 19. Poryazova R, Waldvogel D, Bassetti CL . Sleepwalking in patients with Parkinson disease. Arch Neurol 2007; 64 : 1524 \200\2237 . 20. Scaglione C, Vignatelli L, Plazzi G, et al . REM sleep behavior disorder in Parkinson \200\231s disease: a questionnaire-base d study. Neurol Sci 2005; 25 : 316 \200\2232 1 . 44. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O . Sleep attacks and 21. Meral H, Aydemir T, Ozer F, et al . Relationship between visual halluci- nations and RE M sleep behavior disorder in patients with Parkinson \200\231s disease. Clin Neurol Neurosu rg 2007; 109 : 862 \200\2237 . Parkinson \200\231s disease treatment. Lancet 2000; 355 : 1333 \200\2234 . 45. Schapira AH . Sleep attacks (sleep episodes) with pergolide. Lancet 2000; 355 : 1332 \200\2233 . 22. Wetter TC, Trenkwalder C, Gershanik O, Hogl B . Polysomnographic measures in Parkinson \200\231s disease: a comparison between patients with and without REM sleep disturbances. W ien Klin Wochenschr 2001; 113 : 249 \200\2235 3 . 46. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J . Excessive daytime sleepin ess and sudden-onse t sleep in Parkinson dis- ease: a survey by the Canadian Movement Disor ders Group. JAMA 2002; 287 : 455 \200\2236 3 . 23. Gagnon JF, Bedard MA, Fantini ML, et al . REM sleep behavior disorder and REM sleep wit hout atonia in Parkinson \200\231s disease. Neurology 2002; 59 : 585 \200\2239 . 47. Ferreira JJ, Th alamas C, Montastruc JL, Castro-Caldas A, Rascol O . Levodopa monothera py can induce \200\230sleep attacks \200\231 in Parkinson \200\231s disease patients. J Ne urol 2001; 248 : 426 \200\2237 . 24. Diederich NJ, Vaillant M, Mancuso G, Lyen P, Tiete J . Progressive sleep \200\230destr ucturing \200\231 in Parkinson \200\231s disease. A polysomnographic study in 46 patients. Sleep Med 2005; 6 : 313 \200\22318 . 48. Holloway RG, Shoulson I, Fahn S, et al . Pramipexole vs levodopa as initial treatment f or Parkinson disease: a 4-yea r randomized controlled trial. Arch Neurol 2004; 61 : 1044 \200\2235 3 . Oxford Textbook of Movement Disorders 110 71. Khan NL, Katzenschlager R, Watt H, et al . Olfaction diff erentiates parkin disease fro m early-onse t parkinsonism and Parkinson disease. Neurology 2004; 62 : 1224 \200\2236 . 49. Zesiewicz TA, Sullivan KL, Arnulf I, et al . Practice Parameter. Treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74 : 924 \200\2233 1 . 72. Healy DG, Falchi M, O \200\231Sullivan SS, et al . Phenotype, genotype, and worldwide g enetic penetrance of LRRK2-associate d Parkinson \200\231s disease: a case \200\223contro l study. Lancet Neurol 2008; 7 : 583 \200\2239 0 . 50. Hogl B, Saletu M, Brandauer E, et al . Modafinil for the treatment of daytime sleepines s in Parkinson \200\231s disease: a double-blin d, rand- omized, crossover, placebo-control le d polygraphic trial. Sleep 2002; 25 : 905 \200\2239 . 73. Silveira-Moriyama L, Munhoz RP, de J Carvalho M, et al . Olfactory heterogeneity in LRR K2 related Parkinsonism. Mov Disord 2010; 25 : 2879 \200\2238 3 . 51. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J . Randomized trial of modafi nil for t reating subjective daytime sleepiness in patients with Parkinson \200\231s disease. Mov Dis ord 2003; 18 : 287 \200\2239 3 . 74. McShane RH, Nagy Z, Esiri MM, et al . Anosmia in dementia is associated with Lewy bodie s rather than Alzheimer \200\231s pathology. J Neurol Neurosurg Psychiatry 2001; 70 : 739 \200\2234 3 . 52. Ondo WG, Fayle R, Atassi F, Jankovic J . Modafi nil for daytime somno- lence in Parkins on \200\231s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg P sychiatry 2005; 76 : 1636 \200\2239 . 75. Jost WH . Autonomic dysfunctions in idiopathic Parkinson \200\231s disease. J Neurol 2003; 250 (Suppl 1): I28 \200\2233 0 . 53. Ondo WG, Perkins T, Swick T, et al . Sodium oxybate for excessive day- time sleepiness in Parkinson disease: an open-labe l polysomnographic study. Arch Neurol 2008; 65 : 1337 \200\2234 0 . 76. Magerkurth C, Schnitzer R, Braune S . Symptoms of autonomic failure in Parkinson \200 \231s disease: prevalence and impact on daily life. Clin Auton Res 2005; 15 : 76 \200\2238 2 . 54. Doty RL, Stern MB, Pfeiff er C, Gollomp SM, Hurtig HI . Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson \200\231s disease. J Neurol Neur osurg Psychiatry 1992; 55 : 138 \200\2234 2 . 77. Bonuccelli U, Lucetti C, Del Dotto P, et al . Orthostatic hypotension in de novo Parkinson disease. Arch Neurol 2003; 60 : 1400 \200\2234 . 78. Muller B, Larsen JP, Wentzel-Larsen T, Skeie GO, Tysnes OB . Autonomic and sensory symp toms and signs in incident, untreated Parkinson \200\231s dis- ease: frequent but mild. Mov Disord 2011; 26 : 65 \200\2237 2 . 55. Katzenschlager R, Lees AJ . Olfaction and Parkinson \200\231s syndromes: its role in diff erential diagnosis. Curr Opin Neurol 2004; 17 : 417 \200\2232 3 . 56. Muller A, Mungersdorf M, Reichmann H, Strehle G, Hummel T . Olfactory function in Parki nsonian syndromes. J Clin Neurosci 2002; 9 : 521 \200\2234 . 79. Kaufmann H, Nahm K, Purohit D, Wolfe D . Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 2004; 63 : 1093 \200\2235 . 57. Henderson JM, Lu Y, Wang S, Cartwright H, Halliday GM . Olfactory defi cits and sleep d isturbances in Parkinson \200\231s disease: a case \200\223contro l sur- vey. J Neurol Neur osurg Psychiatry 2003; 74 : 956 \200\2238 . 80. O \200\231Sullivan SS, Holton JL, Massey LA, Williams DR, Revesz T, Lees AJ . Parkinson \200\231s disease with Onuf \200\231s nucleus involvement mimicking multi- ple system atr ophy. J Neurol Neurosurg Psychiatry 2008; 79 : 232 \200\2234 . 81. Abbott RD, Ross GW, Pet rovitch H, et al . Bowel movement frequency in late-lif e and incidental Lewy bodies. Mov D isord 2007; 22 : 1581 \200\2236 . 82. Papapetropoulos S, Paschalis C, Athanassiadou A, et al . Clinical pheno- type in patients with alpha-synuclei n Parkinson \200\231s disease liv ing in Greece in comparison with patients with sporadic Parkinson \200\231s disease. J Neur ol Neurosurg Psychiatry 2001; 70 : 662 \200\2235 . 58. Saifee T, Lees AJ, Silveira-Moriyama L . Olfactory function in Parkinson \200\231s dise ase in ON versus OFF states. J Neurol Neurosurg Psychiatry 2010; 81 : 1293 \200\2235 . 59. Ponsen MM, Stoff ers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW . Idiopathic h yposmia as a preclinical sign of Parkinson \200\231s disease. Ann Neurol 2004; 56 : 173 \200\2238 1 . 60. Ross GW, Petrovitch H, Abbott RD, et al . Association of olfactory dys- function with r isk for future Parkinson \200\231s disease. Ann Neurol 2008; 63 : 167 \200\2237 3 . 83. Singleton A, Gwinn-Hardy K, Sharabi Y, et al . Association between car- diac denervatio n and parkinsonism caused by alpha-synuclei n gene trip- lication. Brain 2004; 127 : 768 \200\2237 2 . 61. Benarroch EE . Olfactory system: functional organization and involve- 84. Albanese A, Valente EM, Romito LM, Bellacchio E, Elia AE, Dallapiccola B . Th e PINK1 p henotype can be indistinguishable from idiopathic Parkinson disease. Neurology 2005; 64 : 1 958 \200\2236 0 . ment in neurodegenerative disease. Neurology 2010; 75 : 1104 \200\2239 . 62. Stern MB, Doty RL, Dotti M, et al . Olfactory function in Parkinson \200\231s dis- ease subtypes. Neurology 1994; 44 : 266 \200\2238 . 85. Goldstein DS, Imrich R, Peckham E, et al . Neurocirculatory and nigros- triatal abnorma lities in Parkinson disease from LRRK2 mutation. Neurology 2007; 69 : 1580 \200\2234 . 63. Iijima M, Kobayakawa T, Saito S, et al . Diff erences in odor identifi cation among cli nical subtypes of Parkinson \200\231s disease. Eur J Neurol 2011; 18 : 425 \200\2239 . 86. Khan NL, Graham E, Critchley P, et al . Parkin disease: a phenotypic study of a large case series. Brain 2003; 126 : 1279 \200\2239 2 . 64. Goldstein DS, Sewell L, Holmes C . Association of anosmia with auto- nomic failure in Parkinson disease. Neurology 2010; 74 : 245 \200\2235 1 . 87. Kagi G, Klein C, Wood NW, et al . Nonmotor symptoms in Parkin gene-relate d parkinsonism. Mov Disord 2010; 25 : 1279 \200\2238 4 . 65. Bohnen NI, Muller ML, Kotagal V, et al . Olfactory dysfunction, central cholinergic int egrity and cognitive impairment in Parkinson \200\231s disease. Brain 2010; 133 : 1747 \200 \2235 4 . 88. Qualman SJ, Haupt HM, Yang P, Hamilton SR . Esophageal Lewy bodies associated with gang lion cell loss in achalasia: similarity to Parkinson \200\231s disease. Gastroenterology 19 84; 87 : 848 \200\2235 6 . 66. Damholdt MF, Borghammer P, Larsen L, Ostergaard K . Odor identifi - cation defi cits id entify Parkinson \200\231s disease patients with poor cognitive performance. Mov Disord 201 1; 26 : 2045 \200\2235 0 . 89. Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ . Parkinson \200\231s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987; 37 : 1253 \200\2235 . 67. Morley JF, Weintraub D, Mamikonyan E, Moberg PJ, Siderowf AD, Duda JE . Olfactory dysfu nction is associated with neuropsychiatric manifesta- tions in Parkinson \200\231s disease. Mov Disord 2011; 26 : 2051 \200\2237 . 90. Jackson M, Lennox G, Balsitis M, Lowe J . Lewy body dysphagia. J Neurol Neurosurg Psychiatry 1995; 58 : 756 \200\2238 . 68. Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N . Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995; 91 : 247 \200\2235 0 . 91. Singaram C, Ashraf W, Gaumnitz EA, et al . Dopaminergic defect of enteric nervous syste m in Parkinson \200\231s disease patients with chronic con- stipation. Lancet 1995; 346 : 8 61 \200\2234 . 69. Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ . Olfactory func- tion distingui shes vascular parkinsonism from Parkinson \200\231s disease. J Neurol Neurosurg Psychiatry 2004; 75 : 1749 \200\2235 2 . 92. Wakabayashi K, Takahashi H . Th e intermediolateral nucleus and Clarke \200\231s column in Parkinson \200\231s disease. Acta Neuropathol 1997; 94 : 287 \200\2239 . 70. Louis ED, Bromley SM, Jurewicz EC, Watner D . Olfactory dysfunction in essential tremor : a defi cit unrelated to disease duration or severity. Neurology 2002; 59 : 1631 \200\223 3 . 93. Iwanaga K, Wakabayashi K, Yoshimoto M, et al . Lewy body-typ e degen- eration in cardia c plexus in Parkinson \200\231s and incidental Lewy body dis- eases. Neurology 1999 12 ;52: 1269 \200\2237 1 . CHAPTER 11 Non-motor Symptom Management in Parkinson \200\231s Disease 111 116. Sakakibara R, Shinotoh H, Uchiyama T, et al . Questionnaire-base d assessment of pelvi c organ dysfunction in Parkinson \200\231s disease. Auton Neurosci 2001; 92 : 76 \200\2238 5 . 94. Benarroch EE, Schmeichel AM, Parisi JE . Involvement of the ventrola- teral medulla in parkinsonism with autonomic failure. Neurology 2000; 54 : 963 \200\2238 . 95. Braak H, de Vos RA, Bohl J, Del Tredici K . Gastric alpha-synuclei n immunoreactive inc lusions in Meissner \200\231s and Auerbach \200\231s plexuses in cases staged for Parkinson \200\231s disease-relate d brain pathology. Neurosci Lett 2006; 396 : 67 \200\2237 2 . 117. Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho RM, Jr, Ribeiro SC, de Carvalho DF . Urinary symptoms in Parkinson \200\231s dis- ease: prevalence and associated factors. Arq Neuropsiquiatr 2003; 61 : 359 \200\2236 3 . 96. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al . Do alpha-synuclei n ag gregates in autonomic plexuses predate Lewy body disorders? A cohort study. Neurology 2007; 68 : 2012 \200\22318 . 118. Wenning GK, Scherfl er C, Granata R, et al . Time course of symptomatic orthostatic hy potension and urinary incontinence in patients with postmortem confi rmed parkinsonian synd romes: a clinicopathological study. J Neurol Neurosurg Psychiatry 1999; 67 : 620 \200\2233 . 97. Orimo S, Uchihara T, Nakamura A, et al . Axonal alpha-synuclei n aggre- gates herald ce ntripetal degeneration of cardiac sympathetic nerve in Parkinson \200\231s disease. Brain 2 008; 131 : 642 \200\2235 0 . 119. Uchiyama T, Sakakibara R, Yamamoto T, et al . Urinary dysfunction in early and untreat ed Parkinson \200\231s disease. J Neurol Neurosurg Psychiatry 2011; 82 : 1382 \200\2236 . 98. Edwards LL, Pfeiff er RF, Quigley EM, Hofman R, Balluff M . Gastrointestinal symptoms in Parkinson \200\231s disease. Mov Disord 1991; 6 : 151 \200\2236 . 120. O \200\231Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira- Moriyama L, Lee s AJ. Nonmotor symptoms as presenting complaints in Parkinson \200\231s disease: A clinicop athological study. Mov Disord 2008; 23: 101 \200\2236. 99. Pfeiff er RF . Gastrointestinal dysfunction in Parkinson \200\231s disease. Lancet Neurol 2003; 2 : 107 \200\2231 6 . 100. Hardoff R, Sula M, Tamir A, et al . Gastric emptying time and gastric motil- ity in pa tients with Parkinson \200\231s disease. Mov Disord 2001; 16 : 1041 \200\2237 . 101. Sonne nberg A, Tsou VT, Muller AD . Th e \200\230institutional colon \200\231: a fre- quent colo nic dysmotility in psychiatric and neurologic disease. Am J Gastroenterol 1994; 89 : 62 \200\2236 . 121. Ransmayr GN, Holliger S, Schletterer K, et al . Lower urinary tract symp- toms in deme ntia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology 2008; 70 : 299 \200\22330 3 . 122. Welsh M, Hung L, Waters CH. Sexuality in women with Parkinson \200\231s dis- ease. Mov Disord 1997; 12 : 923 \200\2237 . 102. Hermanowicz N . Fatal gastroparesis in a patient with Parkinson \200\231s dis- 123. Bronner G, Royter V, Korczyn AD, Giladi N . Sexual dysfunction in ease. Mov Disord 2008; 23 : 152 \200\2233 . Parkinson \200\231s disease. J Sex Marital Th er 2004; 30 : 95 \200\22310 5 . 103. Kaye J, Gage H, Kimber A, Story L, Trend P . Excess burden of constipa- tion in Parki nson \200\231s disease: a pilot study. Mov Disord 2006; 21 : 1270 \200\2233 . 104. Ashraf W, Wszolek ZK, Pfeiff er RF, et al . Anorectal function in fl uc- tuating (on-off ) Parkins on \200\231s disease: evaluation by combined anorectal manometry and electromyography. Mov Disord 1995; 10 : 650 \200\2237 . 105. Bassotti G, Maggio D, Battaglia E, et al . Manometr ic investigation of anorectal function in early and late stage Parkinson \200\231s disease. J Neurol Neurosurg Psychiatry 2000; 68 : 768 \200\2237 0 . 124. Gao X, Chen H, Schwarzschild MA, et al . Erectile function and risk of Parkinson \200\231s disease. Am J Epidemiol 2007; 166 : 1446 \200\2235 0 . 125. Jimenez-Jimenez FJ, Tallon-Barranco A, Cabrera-Valdivia F, Gasalla T, Orti-Pareja M, Z urdo M. Fluctuating penile erection related with levo- dopa therapy. Neurology 1999; 52 : 2 10 . 126. Kanovsky P, Bares M, Pohanka M, Rektor I . Penile erections and hyper- sexuality induc ed by pergolide treatment in advanced, fl uctuating Parkinson \200\231s disease. J Neurol 2 002; 249 : 112 \200\22314 . 106. Sakakibara R, Odaka T, Lui Z, et al . Dietary herb extract dai-kenchu-t o ameliorates constipation in parkinsonian patients (Parkinson \200\231s disease and multiple system atro phy). Mov Disord 2005; 20 : 261 \200\2232 . 127. Suchowersky O, Furtado S, Rohs G . Benefi cial eff ect of intranasal desmopressin for nocturnal polyuria in Parkinson \200\231s disease. Mov Disord 1995; 10 : 337 \200\2234 0 . 107. Mathers SE, Kempster PA, Swash M, Lees AJ . Constipation and para- doxical puborectali s contraction in anismus and Parkinson \200\231s disease: a dystonic phenomenon? J Neurol N eurosurg Psychiatry 1988 ; 51 : 1503 \200\2237 . 128. Zesiewicz TA, Helal M, Hauser RA. Sildenafi l citrate (Viagra) for the treatment of er ectile dysfunction in men with Parkinson \200\231s disease. Mov Disord 2000; 15 : 305 \200 \2238 . 129. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ . Treatment of erectile dysfunct ion with sildenafi l citrate (Viagra) in parkinsonism due to Parkinson \200\231s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg P sychiatry 2001; 71 : 371 \200\2234 . 130. O \200\231Mara G, Lyons D . Postprandial hypoten sion. Clin Geriatr Med 2002; 108. Ashraf W, Pfeiff er RF, Quigley EM. Anorectal manometry in the assess- ment of anorect al function in Parkinson \200\231s disease: a comparison with chronic idiopathic constipati on. Mov Disord 1994 ; 9 : 655 \200\2236 3 . 109. Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves consti- pation in Parkinson \200\231s disease and multiple system atrophy. Mov Disord 2001; 16 : 1176 \200\2237 . 18 : 307 \200\2232 1 . 131. Bleasdale-Barr KM, Mathias CJ . Neck and other muscle pains in auto- nomic failure: th eir association with orthostatic hypotension. J R Soc Med 1998; 91 : 355 \200\2239 . 110. Liu Z, Sakakibara R, Odaka T, et al . Mosapride citrate, a novel 5-HT 4 agonist and pa rtial 5-HT 3 antagonist, ameliorates constipation in par- kinsonian patients. Mov Disord 20 05; 20 : 680 \200\2236 . 132. Oka H, Yoshioka M, Onouchi K, et al . Characteristics of orthostatic 111. Sullivan KL, Staff etti JF, Hauser RA, Dunne PB, Zesiewicz TA . Tegaserod (Zelnorm) fo r the treatment of constipation in Parkinson \200\231s disease. Mov Disord 2006 Jan; 21 : 1 15 \200\22316 . hypotension in Parkinson \200\231s disease. Brain 2007; 130 : 2425 \200\2233 2 . 133. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG . Th e Sydney multicenter study of Parkinson \200\231s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23 : 837 \200\2234 4 . 112. Zangaglia R, Martignoni E, Glorioso M, et al . Macrogol for the treatment of constipat ion in Parkinson \200\231s disease: a randomized placebo-controlle d study. Mov Disord 2007 ; 22 : 1239 \200\2234 4 . 134. Hely MA, Morris JG, Reid WG, Traffi cante R . Sydney Multicenter Study of Parkinson \200\231s disease: non-l-dopa-responsiv e problems dominate at 15 years. Mov Disord 2005; 2 0 : 190 \200\2239 . 113. Soykan I, Sarosiek I, Shiffl ett J, Wooten GF, McCallum RW . Eff ect of chronic oral d omperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parki nson \200\231s disease. Mov Disord 1997; 12 : 952 \200\2237 . 135. Goldstein DS . Orthostatic hypotension as an early fi nding in Parkinson \200\231s disease. Clin Auton Res 2006; 16 : 46 \200\2235 4 . 136. Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST . Orthostatic hypo- tension from sym pathetic denervation in Parkinson \200\231s disease. Neurology 2002; 58 : 1247 \200\2235 5 . 114. Albanese A, Brisinda G, Bentivoglio AR, Maria G . Treatment of outlet obstruction cons tipation in Parkinson \200\231s disease with botulinum neuro- toxin A. Am J Gastroenterol 2 003; 98 : 1439 \200\2234 0 . 137. Oka H, Toyoda C, Yogo M, Mochio S . Cardiovascular dysautonomia in de novo Parkinson \200\231s disease without orthostatic hypotension. Eur J Neurol 2011; 18 : 286 \200\2239 2 . 115. Araki I, Kuno S . Assessment of voiding dysfunction in Parkinson \200\231s dis- ease b y the international prostate symptom score. J Neurol Neurosurg Psychiatry 2000; 68 : 429 \200\2233 3 .